Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer

Patient benefit vs industry benefit finding a balance

Balancing innovation and Common Sense In Oncology (CSO)

Common Sense in Oncology – Why

Integration of evidence-informed decision making into policymaking

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Biostat for Clinician Researchers 1: Correlation and Regression Analysis

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients

Adjuvant radiotherapy has no benefit following radical prostatectomy